Stocks · Healthcare · Biotechnology
United Therapeutics Corporation UTHR
$541.70 -5.19% Close, Oct 2, 2026 · NASDAQ · Market cap $22.99B
High qualityLow risk
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The shares trade at 19.4× trailing earnings, higher than 86% of the company's own readings over the past five years.
- The diluted share count fell 5.2% in a year, mainly through buybacks.
- The company holds net cash of $1.80B (cash above total debt).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 34%
- EPS growth (TTM, YoY)Bottom 49%
- FCF growth (TTM, YoY)Bottom 42%
- Revenue growth, 3-year CAGRTop 34%
- Revenue growth accelerationBottom 30%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 7%
- Gross marginTop 23%
- Operating marginTop 2%
- Cash conversion (OCF / net income)Bottom 36%
- Accruals (lower is better)Bottom 43%
- Net debt / EBITDA (lower is better)Top 18%
- Interest coverTop 3%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 9%
- Free-cash-flow yieldTop 19%
- EBITDA / enterprise valueTop 13%
- Sales / enterprise valueBottom 40%
- P/E vs own 5-year history (lower is better)Bottom 15%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 43%
- 6-month returnBottom 38%
- 1-year return vs S&P 500Top 41%
- Distance from 52-week highTop 17%
- Trend checklist (0–4)Top 20%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 43%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyBottom 21%
- Upside to consensus price targetBottom 19%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 18%
- Maximum drawdown, 3 yearsTop 6%
- Beta vs S&P 500 (lower is better)Top 17%
- Net debt / EBITDA (lower is better)Top 18%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 5.9% | 2.5% | ↓ |
| EPS growth (YoY) | 7.9% | 8.9% | ↑ |
| Gross margin | 89.0% | 86.1% | ↓ |
| Operating margin | 47.0% | 44.5% | ↓ |
| FCF margin | 34.8% | 34.6% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 2.5% | 5.9% | ↓ | Bottom 34% |
| EPS growth (TTM, YoY) | 8.9% | 7.9% | ↑ | Bottom 49% |
| Gross margin | 86.1% | 89.0% | ↓ | Top 23% |
| Operating margin | 44.5% | 47.0% | ↓ | Top 2% |
| Net margin | 41.6% | 40.4% | ↑ | — |
| Free-cash-flow margin | 34.6% | 34.8% | ↓ | — |
| Return on invested capital | 17.7% | — | Top 7% | |
| Revenue growth, 3-year CAGR | 18.0% | — | Top 34% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.29×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -5.2%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 4.9%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -20.7 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -1.09×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 117.0×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 9.54%
- Shareholder yield
- 9.54%
- Share count change, 1 year
- -5.2%
- Share count change, 3-year CAGR
- -2.6%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- +0.3%
- Average 2-day reaction, last 8
- +1.8%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $599.80
- Target vs current price
- +10.7%
- Analysts with a rating
- 30
- Share rating Buy or Strong Buy
- 57%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | +6.0% | +0.1% | -0.6% | -1.2% | — |
| May 6, 2026 | -16.9% | +4.3% | +1.7% | -4.0% | -9.5% |
| Feb 25, 2026 | +8.0% | +13.0% | +5.3% | +12.3% | +19.1% |
| Oct 29, 2025 | +3.9% | +9.6% | +5.3% | +17.0% | +14.0% |
| Jul 30, 2025 | -12.1% | -5.2% | +2.4% | +3.9% | +41.7% |
| Apr 30, 2025 | +5.4% | +0.8% | -1.9% | +4.9% | +1.2% |
| Feb 26, 2025 | -3.3% | -10.8% | -13.7% | -11.4% | -13.4% |
| Oct 30, 2024 | -0.6% | +2.4% | +8.5% | +6.9% | +5.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | $7.27 | $6.86 | +6.0% | $783.3M |
| May 6, 2026 | $5.82 | $7.00 | -16.9% | $781.5M |
| Feb 25, 2026 | $7.70 | $7.13 | +8.0% | $790.2M |
| Oct 29, 2025 | $7.16 | $6.89 | +3.9% | $799.5M |
| Jul 30, 2025 | $6.41 | $7.29 | -12.1% | $798.6M |
| Apr 30, 2025 | $6.63 | $6.29 | +5.4% | $794.4M |
| Feb 26, 2025 | $6.19 | $6.40 | -3.3% | $735.9M |
| Oct 30, 2024 | $6.39 | $6.43 | -0.6% | $748.9M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 19.4× | 15.9× | 86th | Top 9% |
| P/E (forward) | 20.7× | — | — | — |
| EV / EBITDA | 12.8× | — | — | Top 13% |
| EV / Sales | 6.72× | — | — | Bottom 40% |
| Free-cash-flow yield | 4.75% | — | — | Top 19% |
| Earnings yield | 5.15% | — | — | Top 9% |
P/E over the past five years
Range 11.0× – 22.1× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +23.6%
- Earnings per share growth (TTM)
- +8.9%
- Change in P/E multiple
- +68.9%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✗ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 3
- Days above the 200-day average
- 3
- 50-day average slope (20 days)
- -3.0%
- 200-day average slope (20 days)
- +0.4%
- Distance from 50-day average
- +6.0%
- Distance from 200-day average
- +3.1%
- RSI (14)
- 60.0
- Relative volume
- 1.23×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 36.9%
- Volatility vs own 5-year history
- 73th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.52
- Correlation with S&P 500
- 0.21
- Current drawdown from 1-year high
- -9.2%
- Maximum drawdown, 3 years
- -33.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Nov 8, 2024 | Jul 31, 2025 | -33.0% | 179 days | 35 days (Sep 19, 2025) |
| Dec 9, 2022 | May 30, 2023 | -26.2% | 116 days | 261 days (Jun 12, 2024) |
| Dec 31, 2021 | Mar 1, 2022 | -23.1% | 40 days | 59 days (May 24, 2022) |
| May 6, 2026 | Sep 24, 2026 | -20.9% | 97 days | Not yet recovered |
| Apr 21, 2021 | Jun 8, 2021 | -19.6% | 33 days | 42 days (Aug 6, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $22.99B
- P/E (TTM)
- 19.4
- EPS, diluted (TTM)
- $27.91
- Revenue (TTM)
- $3.15B
- 52-week range
- $409.07 – $609.35
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $1.69B | $1.94B | $2.33B | $2.88B | $3.18B |
| Gross profit | $1.56B | $1.79B | $2.07B | $2.57B | $2.80B |
| Operating income | $555.9M | $979.7M | $1.18B | $1.38B | $1.52B |
| Net income | $475.8M | $727.3M | $984.8M | $1.20B | $1.33B |
| EPS (diluted) | $10.06 | $15.00 | $19.81 | $24.64 | $27.86 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $748.9M | $735.9M | $794.4M | $798.6M | $799.5M | $790.2M | $781.5M | $783.3M |
| Net income | $309.1M | $301.3M | $322.2M | $309.5M | $338.7M | $364.3M | $274.9M | $333.0M |
| EPS (diluted) | $6.39 | $6.19 | $6.63 | $6.41 | $7.16 | $7.66 | $5.82 | $7.27 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $598.2M | $802.5M | $978.0M | $1.33B | $1.56B |
| Capital expenditure | -$120.8M | -$138.8M | -$230.4M | -$246.5M | -$520.5M |
| Free cash flow | $477.4M | $663.7M | $747.6M | $1.08B | $1.04B |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | -$10.8M | -$11.4M | -$13.8M | -$1.01B | -$816.9M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $2.66B
- Total assets
- $7.22B
- Total liabilities
- $819.8M
- Total debt
- $0
- Net debt
- -$1.80B
- Shareholders’ equity
- $6.40B
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 2,800,470
- Days to cover
- 3.90
- Change vs previous report
- +36.0%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Sep 23, 2009
- 2-for-1